May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
February 3rd 2023
August 26th 2022
July 11th 2022
Three Experts Weigh In on Plasma-Based Molecular Profiling in OncologyFebruary 3rd 2015
Guardant360 is a highly sensitive digital sequencing system that requires only a 10 mL blood sample, and allows for simultaneous assessment of more than 60 actionable genes in circulating, cell-free DNA.
High Levels of KRAS in ctDNA of Pancreatic Cancer May Mean Lower OSJanuary 21st 2015
During a retrospective study of 182 patients with nonresectable pancreatic cancer, a negative association was found between baseline circulating tumor (ct)DNA KRAS counts in plasma and overall survival (OS), which indicates that patients with lower KRAS burden in ctDNA survive longer.
Novartis Buys Into Gene Editing With CRISPR/Cas9January 12th 2015
The start of 2015 brought news from Novartis that it had signed an agreement with Intellia Therapeutics and Caribou Biosciences to license its proprietary CRISPR/Cas9 gene editing platform to develop novel treatments for chronic genetic-based diseases.
Cell-Free DNA Detection in Histiocytic Disorders May Transform Diagnosis and TreatmentJanuary 8th 2015
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are characterized by a high frequency of BRAFV600E mutations, which are responsive to treatment with BRAF inhibitors such as vemurafenib.
Gene Test Predicts Risk of Recurrence for DCIS PatientsDecember 13th 2014
A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk. These results were presented at the 2014 San Antonio Breast Cancer Symposium.
Next-Generation Sequencing Tests in NSCLCNovember 7th 2014
A key to improved outcomes for patients with non-small cell lung cancer (NSCLC) is the ability to identify the wide spectrum of genetic changes present in tumors. Doing so will guide treatment decisions and influence the development of much-needed additional targeted therapies.
The Impact of Neuroendocrine Tumor Heterogeneity During Disease ProgressionOctober 13th 2014
David S. Klimstra, MD, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, at the 2014 NANETS Symposium.
Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian TumorsSeptember 6th 2014
The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.
Selecting Patients for Treatment with CO-1686September 3rd 2014
Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
New Insights From ENCODE Datasets, NIH Issues Finalized Genomic Data Sharing PolicySeptember 2nd 2014
A series of papers have been published in the journal Nature in which researchers conducted detailed comparisons of the worm, fly, and human genomes using data from the ENCODE and modENCODE projects.
The Importance of Testing for BRAF Status in CRC PatientsAugust 13th 2014
Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.